JPMorgan Plans More Asia-Pacific Hiring in 2027 as Corporate Banking Revenue Surges 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Airbus Joins Air India A320 Altitude Drop Probe 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
The US government will pay $2.1 billion to Sanofi SA and GlaxoSmithKline Plc for 100 million doses of COVID-19 vaccines covering 50 million people and underwrite the drug makers’ testing and manufacturing.
Each of the 50 million Americans will receive two doses.
The deal will cost around $42 per person inoculated.
Sanofi and GlaxoSmithKline would conduct clinical trials for the vaccine in September.
The US government has the option to purchase an additional 500 million doses at an unspecified price.
Sanofi executive Clement Lewin said the companies have yet to agree with the government on the price for the additional doses.
According to Alex Azar, secretary of the US Department of Health and Human Services, the product being developed by Sanofi and GSK has the potential to bring hundreds of millions of safe and effective doses.
The award is so far the biggest from the White House initiative to accelerate access to vaccines and treatments to fight COVID-19 dubbed ‘Operation Warp Speed.’
Last week, the US agreed to pay Pfizer Inc and BioNTech SE $2 billion deal for 50 million courses of the potential vaccine.
The price per patient is $40.
The coronavirus has infected 4.5 million Americans and killed over 152,000 Americans.
The US Centers for Disease Control forecasts between 168,000 and 182,000 total fatalities by August 22.
The deaths will supposedly rise fastest in Alabama, Tennessee, Washington state, Kentucky, New Jersey, and Puerto Rico.
